Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths
- PMID: 38698324
- PMCID: PMC11067253
- DOI: 10.1186/s12879-024-09304-1
Direct impact of COVID-19 vaccination in Chile: averted cases, hospitalizations, ICU admissions, and deaths
Abstract
Background: Chile rapidly implemented an extensive COVID-19 vaccination campaign, deploying a diversity of vaccines with a strategy that prioritized the elderly and individuals with comorbidities. This study aims to assess the direct impact of vaccination on the number of COVID-19 related cases, hospital admissions, ICU admissions and deaths averted during the first year and a half of the campaign.
Methods: Via Chile's transparency law, we obtained access to weekly event counts categorized by vaccination status and age. Integrating this data with publicly available census and vaccination coverage information, we conducted a comparative analysis of weekly incidence rates between vaccinated and unvaccinated groups from December 20, 2020 to July 2, 2022 to estimate the direct impact of vaccination in terms of the number of cases, hospitalizations, ICU admissions and deaths averted, using an approach that avoids the need to explicitly specify the effectiveness of each vaccine deployed.
Results: We estimated that, from December 20, 2020 to July 2, 2022 the vaccination campaign directly prevented 1,030,648 (95% Confidence Interval: 1,016,975-1,044,321) cases, 268,784 (95% CI: 264,524-273,045) hospitalizations, 85,830 (95% CI: 83,466-88,194) ICU admissions and 75,968 (95% CI: 73,909-78,028) deaths related to COVID-19 among individuals aged 16 years and older. This corresponds to a reduction of 26% of cases, 66% of hospital admissions, 70% of ICU admissions and 67% of deaths compared to a scenario without vaccination. Individuals 55 years old or older represented 67% of hospitalizations, 73% of ICU admissions and 89% of deaths related to COVID-19 prevented.
Conclusions: This study highlights the role of Chile's vaccination campaign in reducing COVID-19 disease burden, with the most substantial reductions observed in severe outcomes.
Keywords: Averted events; COVID-19; Cases averted; Deaths averted; Hospitalizations averted; ICU admissions averted; SARS-CoV-2; Vaccine.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures



Similar articles
-
Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.Vaccine. 2025 Mar 7;49:126808. doi: 10.1016/j.vaccine.2025.126808. Epub 2025 Jan 30. Vaccine. 2025. PMID: 39889531 Free PMC article.
-
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.Lancet Infect Dis. 2022 Mar;22(3):357-366. doi: 10.1016/S1473-3099(21)00566-1. Epub 2021 Sep 22. Lancet Infect Dis. 2022. PMID: 34562375 Free PMC article.
-
The impact of the COVID-19 vaccination programme on symptomatic and severe SARS-CoV-2 infection during a period of Omicron variant dominance in Ireland, December 2021 to March 2023.Euro Surveill. 2024 Jul;29(28):2300697. doi: 10.2807/1560-7917.ES.2024.29.28.2300697. Euro Surveill. 2024. PMID: 38994604 Free PMC article.
-
Assessing the impact of COVID-19 passes and mandates on disease transmission, vaccination intention, and uptake: a scoping review.BMC Public Health. 2023 Nov 17;23(1):2279. doi: 10.1186/s12889-023-17203-4. BMC Public Health. 2023. PMID: 37978472 Free PMC article.
-
The lifestyle health index in the context of COVID-19 mortality and vaccination in the United States: A syndemic not to be repeated.Curr Probl Cardiol. 2024 Sep;49(9):102728. doi: 10.1016/j.cpcardiol.2024.102728. Epub 2024 Jun 27. Curr Probl Cardiol. 2024. PMID: 38944225 Review.
Cited by
-
Early mutational signatures and transmissibility of SARS-CoV-2 Gamma and Lambda variants in Chile.Sci Rep. 2024 Jul 11;14(1):16000. doi: 10.1038/s41598-024-66885-2. Sci Rep. 2024. PMID: 38987406 Free PMC article.
-
Causal Estimands for Analyses of Averted and Avertible Outcomes due to Infectious Disease Interventions.Epidemiology. 2025 May 1;36(3):363-373. doi: 10.1097/EDE.0000000000001839. Epub 2025 Jan 24. Epidemiology. 2025. PMID: 39855261 Free PMC article.
References
-
- World Health Organization (WHO). Situation reports COVID-19. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio....
-
- Cifras Oficiales. Gobierno de Chile. https://www.gob.cl/pasoapaso/cifrasoficiales/. Accessed 11 Mar 2024.
-
- Paso a Paso - Gob.cl. Gobierno de Chile. https://www.gob.cl/pasoapaso/. Accessed 12 Mar 2024.
-
- A partir del 1 de octubre la mascarilla ya no es obligatoria: conozca cuál es la excepción y todas las dudas sobre la medida. Gobierno de Chile. https://www.gob.cl/noticias/partir-de-hoy-la-mascarilla-no-es-obligatori.... Accessed 12 Mar 2024.
Publication types
MeSH terms
Substances
Grants and funding
- postdoctoral fellowship 3200116/Agencia Nacional de Investigación y Desarrollo
- COVID0960/Agencia Nacional de Investigación y Desarrollo
- COVID0960/Agencia Nacional de Investigación y Desarrollo
- - Millennium Science Initiative Program - ICN2021_044/Agencia Nacional de Investigación y Desarrollo
- COVID0960/Agencia Nacional de Investigación y Desarrollo
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous